1. 125P A phase IIa study of the novel immunogenic cell death (ICD) inducer PT-112 plus avelumab ("PAVE") in advanced non-small cell lung cancer (NSCLC) patients (pts). (December 2022) Authors: Imbimbo, M.; Ghisoni, E.; Mulvey, A.; Bouchaab, H.; Mederos Alfonso, N.; Karp, D.; Camidge, D.R.; Mansfield, A.S.; Yim, C.Y.; Ames, T.D.; Price, M.; Baeck, J.; O'Donnell, J.F.; Peters, S. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Characterization of differential metabolic phenotypes and PT-112-induced mitochondrial effects in human prostate cancer cells. (October 2022) Authors: Soler Agesta, R.; Moreno-Loshuertos, R.; Marco-Brualla, J.; Junquera, C.; Martínez De Mena, R.; Enríquez, J.A.; Yim, C.Y.; Price, M.R.; Ames, T.D.; Jimeno, J.; Anel, A. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗